News Image

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Provided By GlobeNewswire

Last update: Mar 6, 2025

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 –

– VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and Rare Pediatric Disease designation for retinoblastoma –

Read more at globenewswire.com

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (6/26/2025, 7:05:10 PM)

After market: 0.4472 +0.01 (+1.64%)

0.44

+0.01 (+2.3%)



Find more stocks in the Stock Screener

Follow ChartMill for more